|
Neutrophil
|
|
1
|
MSCs
|
Have protective effects on neutrophil function and lifespan
|
[56]
|
|
2
|
MSCs
|
Reduce terminal complement activation complex C5b-9 to inhibit neutrophils accumulation
|
[57]
|
|
3
|
ADSCs
|
Decrease neutrophils apoptosis and increased their phagocytosis capacity
|
[58]
|
|
4
|
LPS-treated macrophages
|
Induce cytokine production and neutrophil migration
|
[59]
|
|
Macrophage
|
|
1
|
DPSCs
|
Facilitate macrophages to convert from M1 phenotype to M2 phenotype
|
[47]
|
|
2
|
TNF-α induced GMSCs
|
Induce anti-inflammatory M2 macrophage polarization
|
[50]
|
|
3
|
MSCs
|
Modify the polarization of M1 macrophages to M2 macrophages via shuttling miR-182
|
[60]
|
|
4
|
BMSCs
|
Increase M2 macrophage polarization
|
[61]
|
|
5
|
BMSCs
|
Inhibit M1 polarization and promotes M2 polarization in a murine alveolar macrophage cell line by inhibiting cellular glycolysis
|
[62]
|
|
6
|
FNDC5 pre-conditioned BMSCs
|
Play anti-inflammation effects and promote M2 macrophage polarization via NF-κB signaling pathway and Nrf2/HO-1 axis
|
[63]
|
|
7
|
hUCMSCs
|
Facilitate CD163 + M2 macrophage polarization, reduced inflammation, and increases anti-inflammatory responses
|
[64]
|
|
8
|
hUCMSCs
|
Inhibit M1 polarization and promoted M2 polarization through tumor necrosis factor receptor-associated factor 1 (TRAF1)
|
[65]
|
|
9
|
ADSCs
|
Upregulate mRNA expression of M2 macrophages
|
[66]
|
|
10
|
ADSCs
|
Induce anti-inflammatory M2 phenotypes through the transactivation of arginase-1 by Exo-carried active STAT3
|
[67]
|
|
11
|
ADSCs
|
Polarize macrophage to an anti-inflammatory phenotype via regulating the Nrf2/HO-1 expression
|
[68]
|
|
12
|
GMSCs
|
Facilitate macrophages to convert from M1 phenotype to M2 phenotype
|
[69]
|
|
Dendritic cell
|
|
1
|
MSCs
|
Decrease DC surface marker expression and modulates DC-induced immune responses
|
[70]
|
|
2
|
hUCMSCs
|
Suppress maturation and activation of DCs, and decreases the expression level of IL-23
|
[71]
|
|
3
|
regDCs
|
Suppress maturation of recipient DCs resulting in inhibition of bone resorptive cytokines
|
[72]
|
|
4
|
LECs
|
Promote the directional migratory in a CX3CL1/fractalkine-dependent fashion
|
[73]
|
|
T lymphocyte
|
|
1
|
MSCs
|
Increase Treg cell populations, inhibit T lymphocyte proliferation in a dose-dependent manner and decreases the percentage of CD4 + and CD8 + T cell subsets
|
[74]
|
|
2
|
MSCs
|
Upregulate IL-10 and TGF-β1 to promote proliferation and immune-suppression capacity of Tregs
|
[75]
|
|
3
|
MSCs
|
Inhibit the differentiation of Th2 cells via the regulation of the miR-146a-5p/SERPINB2 pathway
|
[76]
|
|
4
|
PDLSCs
|
Alleviate inflammatory microenvironment and keep Th17/Treg balance via Th17/Treg/miR‐155‐5p/SIRT1 regulatory network
|
[77]
|
|
5
|
CD137-modified ECs
|
Promote Th17 cell differentiation via NF-КB pathway mediated IL-6 expression
|
[78]
|
|
B lymphocyte
|
|
1
|
MSCs
|
Upregulate Breg-like cells in lymph nodes
|
[74]
|
|
Osteoclast
|
|
1
|
TNF-α-preconditioned GMSCs
|
Inhibit osteoclastogenic activity via exosomal miR-1260b to target Wnt5a-mediated RANKL pathway and
|
[50]
|
|
2
|
regDC
|
Result in inhibition of bone resorptive cytokines and reduces in osteoclastic bone loss
|
[72]
|
|
3
|
CMS-treated BMSCs
|
Impair osteoclast differentiation via inhibiting the RANKL-induced nuclear factor kappa-B (NF-κB) signaling pathway
|
[79]
|
|
4
|
ADSCs
|
Suppress NLRP3 inflammasome activation in osteoclasts and reduces bone resorption and recover bone loss
|
[80]
|
|
5
|
ADSCs
|
Antagonize osteocyte-mediated osteoclastogenesis
|
[81]
|
|
6
|
ADSCs
|
Inhibit pro-inflammatory cytokines production in high glucose-treated osteoclasts and restrains bone resorption
|
[82]
|
|
7
|
osteoblast
|
Inhibit the osteoclast differentiation via miR-503-3p/Hpse axis
|
[83]
|
|
8
|
EPCs
|
Promote bone repair by enhancing recruitment and differentiation of osteoclast precursors through LncRNA-MALAT1
|
(84)
|
